European Archives - Page 1095 of 1615 - European Medical Journal

Physical Activity Level and Factors Affecting Exercise Participation among Nigerian Adults with and Without Diabetes

Noncommunicable diseases (NCD) account for approximately 71% of all deaths globally. Cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes are the four most important NCD and contributors to the burden of disease…

EMJ Podcast: Sky High Health

Jonathan talks to Richard Jenkins, Chief Medical Officer, Emirates, to discuss innovation in healthcare, the impact of COVID-19 on the aviation sector, and how to safeguard the physical and mental health of pilots and cabin crew as they face the greatest challenge to commercial aviation in recent history.

Faecal Microbiome Differences in Healthy and Food-allergic Twins

FOOD allergy affects up to 26 million members of the European population and poses a substantial public health burden. Fortunately, researchers from…

Could a Novel Immunotherapy Approach Help Combat Cat Allergy?

CAT allergies are among the most common allergies, affecting between 10 and 20% of the global population. Symptoms range from mild-to-moderate conditions…

Clinical Presentation and Management of Non-Dystrophic Myotonias

This webinar provides practical guidance for diagnosing and managing non-dystrophic myotonia (NDM), and is particularly aimed at neurologists not specifically specialised in neuromuscular disease.

TDM and T2T – Perfect Partners?

This webinar opened with an introduction to therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) by Dr Baert, as well as an explanation…

EMJ Gastroenterology 10 [Supplement 1] 2021

This medical education webinar, hosted by EMG-Health on 17th November 2020, sought to educate the virtual audience on therapeutic drug monitoring (TDM)…

Bladder

WEBINAR: Overactive Bladder: Evaluation and Management

The second part of this webinar on overactive bladder discusses the evaluation and management of this condition. Presented by Alan Wein from the…

EMJ Dermatology 9 [Supplement 1] 2021 new feature

EMJ Dermatology 9 [Supplement 1] 2021

At the 2020 European Academy of Dermatology and Venerology (EADV) Virtual Congress, data for 5-year efficacy and safety of tildrakizumab in adults…

Long-term Efficacy and Safety of Tildrakizumab: 5-year Results from the reSURFACE 1 and 2 Phase III Trials in Patients with Moderate-to-severe Plaque Psoriasis

Psoriasis, a chronic systemic inflammatory disease with skin manifestations, can be an impediment to daily life. Accordingly…